Immunic schedules November 12 results for Immunic stock
Published on 10/15/2026 at 21:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSResults date and valuation
- Immunic's next reporting date is November 12, 2026.
- Immunic's market capitalization was USD 96.5 million on October 15, 2026.
- Immunic stock costs EUR 6.28 at Lang & Schwarz on October 15, 2026 at 9:34 p.m. CEST.
- MarketBeat listed a USD 35.43 average analyst target on October 9, 2026.
Immunic's next reporting date is November 12, 2026, according to ToAlpha. That date gives investors a defined calendar point for the late-stage biotechnology company's next update. Immunic stock was trading at EUR 6.28 at Lang & Schwarz on October 15, 2026 at 9:34 p.m. CEST.
Cash supports the clinical program
Immunic reported cash and cash equivalents of USD 155.1 million as of June 30, 2026. Operating cash flow was negative USD 31.0 million in the second quarter of 2026, while net loss reached USD 34.1 million for the same period. Those figures frame the importance of the November reporting date because the company is funding late-stage trials while preparing additional development work.
Range and trading activity
On Nasdaq, Immunic last traded at USD 7.07 on October 15, 2026 at 3:39 p.m. ET. The stock's 52-week range was USD 5.06 to USD 17.43 on October 15, 2026. Trading volume reached 230,534 shares against an average volume of 300,281 shares, placing the session below its recent activity average.
The company is developing oral therapies for neurologic diseases, led by vidofludimus calcium in Phase 3 trials, according to Immunic. The investor page identifies Nasdaq under the ticker IMUX and describes the program as targeting multiple sclerosis.
Valuation and analyst view
Immunic's market capitalization was USD 96.5 million on October 15, 2026. Its trailing price-to-earnings ratio was minus 1.47, reflecting the reported loss, while the dividend yield was 0.00 percent. MarketBeat reported on October 9, 2026 that twelve brokerages had an average 12-month target of USD 35.43 and a Buy consensus.
Next reporting date approaches
The November 12, 2026 date is the next scheduled reporting point identified for Immunic. Investors will have the cash balance, quarterly loss and operating cash flow as the key figures for assessing the company's funding position.
Price and market context
Immunic stock was trading at EUR 6.28 at Lang & Schwarz on October 15, 2026 at 9:34 p.m. CEST. The quote remains the clearest same-day market reference for German investors, while the Nasdaq figures provide the company's home-market context.
The further course of trading is shown by the continuously updated real-time quote of Immunic stock.
Immunic market data
- Company: Immunic, Inc.
- ISIN: US4525EP2001
- Ticker: IMUX
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 9:34 p.m. CEST): EUR 6.28
- Market capitalization: USD 96.5 million (as of October 15, 2026)
- 52-week range: USD 5.06-USD 17.43 (as of October 15, 2026)
- Sector / Industry: Health Care / Biotechnology
- Next earnings date: November 12, 2026
Market context: Market report S&P 500.
